Stephan will take over from Jean Bléhaut, who leaves the company after a career spanning more than 25 years.
Stephan Haitz has a 20+ years business career in the pharmaceutical industry where he held various management positions within global CDMOs such as Solvias, Lonza and Cambrex.
He holds a PhD and Master in organic chemistry and a Bachelor of Science in economics. Most recently, Stephan worked as President Drug Substance CDMO Commercial at Cambrex.
“I’d like to warmly thank Jean for many years of service at Novasep and wish him the best for the future. I’m now looking forward to entrusting the reins of the BU to Stephan to further consolidate the company’s position as a leader in the CDMO market, while bringing new energy and ideas,” stated Dr Sylke Hassel, CEO at Axplora.
“Stephan will work closely with the Executive Committee and particularly with Dr. Pere Paton, our Chief Operations Officer.”
“I am thrilled to join Axplora at a time when bringing drugs to patients globally is more important than ever. Thanks to Axplora’s wide range of technical capabilities and manufacturing excellence, the Novasep CDMO BU is well suited to support customers with developing and delivering innovative API´s and intermediates,” said Dr Stephan Haitz.
“I am excited to be a part of such an experienced Management team and working closely with Pere to continue building the organisation and driving its growth as a leading CDMO.”
“I look forward to working closely with Stephan to develop and implement our operations strategy and vision within the CDMO BU, strengthening our manufacturing network to serve our clients and their patients,” asserts Dr Pere Paton.
